Glucocerebrosidase deficiency leads to neuropathology via cellular immune activation
PLOS Genetics · 2024
DOI: 10.1371/journal.pgen.1011105 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, 2024. Verfasst von Evelyn S Vincow und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America. Hauptthemen laut MEDLINE: Glucosylceramidase, Macrophage Activation, Disease Models, Animal, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Mutations in GBA ( glucosylceramidase beta ), which encodes the lysosomal enzyme glucocerebrosidase (GCase), are the strongest genetic risk factor for the neurodegenerative disorders Parkinson’s disease (PD) and Lewy body dementia. Recent work has suggested that neuroinflammation may be an important factor in the risk conferred by GBA mutations. We therefore systematically tested the contributions of immune-related genes to neuropathology in a Drosophila model of GCase deficiency. We identified target immune factors via RNA-Seq and proteomics on heads from GCase-deficient flies, which revealed both increased abundance of humoral factors and increased macrophage activation. We then manipulated the identified immune factors and measured their effect on head protein aggregates, a hallmark of neurodegenerative disease. Genetic ablation of humoral (secreted) immune factors did not suppress the development of protein aggregation. By contrast, re-expressing Gba1b in activated macrophages suppressed head protein aggregation in Gba1b mutants and rescued their lifespan and behavioral deficits. Moreover, reducing the GCase substrate glucosylceramide in activated macrophages also ameliorated Gba1b mutant phenotypes. Taken together, our findings show that glucosylceramide accumulation due to GCase deficiency leads to macrophage activation, which in turn promotes the development of neuropathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
- Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, United States of America.
ORCID-Profile: Evelyn S Vincow, Ruth E Thomas, Gautam Pareek, Theo K Bammler, James MacDonald, Leo J Pallanck
Förderung
- NIA NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Vincow, E. S., Thomas, R. E., Milstein, G., Pareek, G., Bammler, T. K., MacDonald, J., & Pallanck, L. J. (2024). Glucocerebrosidase deficiency leads to neuropathology via cellular immune activation. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1011105
Vancouver
Vincow ES, Thomas RE, Milstein G, Pareek G, Bammler TK, MacDonald J, et al. Glucocerebrosidase deficiency leads to neuropathology via cellular immune activation. PLOS Genetics. 2024. doi:10.1371/journal.pgen.1011105
BibTeX
@article{Vincow2024,
author = {Vincow, Evelyn S and Thomas, Ruth E and Milstein, Gillian and Pareek, Gautam and Bammler, Theo K and MacDonald, James and Pallanck, Leo J},
title = {Glucocerebrosidase deficiency leads to neuropathology via cellular immune activation},
journal = {PLOS Genetics},
year = {2024},
doi = {10.1371/journal.pgen.1011105}
}
EUVIMED